A randomized clinical trial of α1-antitrypsin augmentation therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A randomized clinical trial of α1-antitrypsin augmentation therapy. / Dirksen, Asger; Dijkman, Joop H.; Madsen, Flemming; Stoel, Berend; Hutchison, Duncan C.S.; Ulrik, Charlotte S.; Skovgaard, Lene T.; Kok-Jensen, Axel; Rudolphus, Arjan; Seersholm, Niels; Vrooman, Henri A.; Reiber, Johan H.C.; Hansen, Niels C.; Heckscher, Thomas; Viskum, Kaj; Stolk, Jan.
In: American Journal of Respiratory and Critical Care Medicine, Vol. 160, No. 5 I, 1999, p. 1468-1472.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A randomized clinical trial of α1-antitrypsin augmentation therapy
AU - Dirksen, Asger
AU - Dijkman, Joop H.
AU - Madsen, Flemming
AU - Stoel, Berend
AU - Hutchison, Duncan C.S.
AU - Ulrik, Charlotte S.
AU - Skovgaard, Lene T.
AU - Kok-Jensen, Axel
AU - Rudolphus, Arjan
AU - Seersholm, Niels
AU - Vrooman, Henri A.
AU - Reiber, Johan H.C.
AU - Hansen, Niels C.
AU - Heckscher, Thomas
AU - Viskum, Kaj
AU - Stolk, Jan
PY - 1999
Y1 - 1999
N2 - We have investigated whether restoration of the balance between neutrophil elastase and its inhibitor, α1-antitrypsin, can prevent the progression of pulmonary emphysema in patients with α1-antitrypsin deficiency. Twenty-six Danish and 30 Dutch ex-smokers with α1-antitrypsin deficiency of PI*ZZ phenotype and moderate emphysema (FEV1 between 30% and 80% of predicted) participated in a double-blind trial of α1-antitrypsin augmentation therapy. The patients were randomized to either α1-antitrypsin (250 mg/kg) or albumin (625 mg/kg) infusions at 4-wk intervals for at least 3 yr. Self-administered spirometry performed every morning and evening at home showed no significant difference in decline of FEV1 between treatment and placebo. Each year, the degree of emphysema was quantified by the 15th percentile point of the lung density histogram derived from computed tomography (CT). The loss of lung tissue measured by CT (mean ± SEM) was 2.6 ± 0.41 g/L/yr for placebo as compared with 1.5 ± 0.41 g/L/yr for α1- antitrypsin infusion (p = 0.07). Power analysis showed that this protective effect would be significant in a similar trial with 130 patients. This is in contrast to calculations based on annual decline of FEV1 showing that 550 patients would be needed to show a 50% reduction of annual decline. We conclude that lung density measurements by CT may facilitate future randomized clinical trials of investigational drugs for a disease in which little progress in therapy has been made in the past 30 yr.
AB - We have investigated whether restoration of the balance between neutrophil elastase and its inhibitor, α1-antitrypsin, can prevent the progression of pulmonary emphysema in patients with α1-antitrypsin deficiency. Twenty-six Danish and 30 Dutch ex-smokers with α1-antitrypsin deficiency of PI*ZZ phenotype and moderate emphysema (FEV1 between 30% and 80% of predicted) participated in a double-blind trial of α1-antitrypsin augmentation therapy. The patients were randomized to either α1-antitrypsin (250 mg/kg) or albumin (625 mg/kg) infusions at 4-wk intervals for at least 3 yr. Self-administered spirometry performed every morning and evening at home showed no significant difference in decline of FEV1 between treatment and placebo. Each year, the degree of emphysema was quantified by the 15th percentile point of the lung density histogram derived from computed tomography (CT). The loss of lung tissue measured by CT (mean ± SEM) was 2.6 ± 0.41 g/L/yr for placebo as compared with 1.5 ± 0.41 g/L/yr for α1- antitrypsin infusion (p = 0.07). Power analysis showed that this protective effect would be significant in a similar trial with 130 patients. This is in contrast to calculations based on annual decline of FEV1 showing that 550 patients would be needed to show a 50% reduction of annual decline. We conclude that lung density measurements by CT may facilitate future randomized clinical trials of investigational drugs for a disease in which little progress in therapy has been made in the past 30 yr.
UR - http://www.scopus.com/inward/record.url?scp=0032724157&partnerID=8YFLogxK
U2 - 10.1164/ajrccm.160.5.9901055
DO - 10.1164/ajrccm.160.5.9901055
M3 - Journal article
C2 - 10556107
AN - SCOPUS:0032724157
VL - 160
SP - 1468
EP - 1472
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 5 I
ER -
ID: 259164811